Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance. The approach is especially popular among telemedicine physicians, who ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Zepbound is a GLP-1 agonist containing tirzepatide ... and 3.2% (with diabetes). Starting dose: 2.5 mg weekly, increasing to 5 mg after 4 weeks. Doses may continue to increase to a maximum ...

while Zepbound pens are available in all doses. A doctor will recommend which dose a person should start with. Generally, Zepbound starter doses will be the lowest dose available. You will then ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...